CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
We have now added a new section called the "Assay History List" to the "At A Gla...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...